NA
ATOS icon

NewEdge Advisors’s Atossa Therapeutics ATOS Stock Holding History

NewEdge Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75K Hold
333
– – ﹤0.01% 3831
2025
Q4 		$2.95K Hold
333
– – ﹤0.01% 3807
2025
Q3 		$4.33K Hold
333
– – ﹤0.01% 3575
2025
Q2 		$4.15K Hold
333
– – ﹤0.01% 3456
2025
Q1 		$3.37K Hold
333
– – ﹤0.01% 3403
2024
Q4 		$4.72K Hold
333
– – ﹤0.01% 3255
2024
Q3 		$7.6K Sell
333
-667
-67% -$13.5K ﹤0.01% 3022
2024
Q2 		$17.9K Buy
+1,000
New +$22.1K ﹤0.01% 2659

Other funds holding ATOS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

NewEdge Advisors's ATOS Position: Q1 2026 in Review

NewEdge Advisors held its Atossa Therapeutics (ATOS) position steady in Q1 2026 at 333 shares worth $1.75K. The position accounts for ﹤0.01% of the portfolio, ranked #3831.

NewEdge Advisors first reported a position in ATOS in Q2 2024 and has held it in 8 quarters since. The position peaked at $17.9K in Q2 2024. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • NewEdge Advisors held 333 shares of Atossa Therapeutics worth $1.75K as of Q1 2026.
  • NewEdge Advisors left its Atossa Therapeutics share count unchanged in Q1 2026.
  • Atossa Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3831 holding.
  • NewEdge Advisors first reported a position in Atossa Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • NewEdge Advisors's Atossa Therapeutics position peaked at $17.9K in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.